At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Triheptanoindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Compatibility of Triheptanoin (C7) With the Ketogenic Diet in Patients Diagnosed With Glucose Transporter Type 1 Deficiency
University of Texas Southwestern Medical Center·interventional·Posted Oct 4, 2017·Updated Jan 17, 2024
In Brief
A Phase 2 clinical trial evaluating Triheptanoin for GLUT1DS1. Completed, enrolled 10 participants across 1 site.
Detailed Summary
To explore triheptanoin (C7 oil) compatibility with the ketogenic diet by evaluating EEG, and seizure rate, glycemia and ketosis in proven G1D patients receiving a ketogenic diet.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGLUT1DS1
CountriesUnited States
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedOct 2017
Enrollment StartJun 2018
Primary CompletionJun 2021
Study CompletionJul 2022
TodayJul 2026
First PostedOct 4, 2017
Enrollment StartJun 5, 2018
Primary CompletionJun 18, 2021
Study CompletionJul 31, 2022
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 8.7 years ago
Interventions
Triheptanoindrug
Dietary supplementation with triheptanoin